Progesterone Types Compared: Micronized, Synthetic Progestins & Compounded Options

Understanding the different progesterone types matters because the choice of progesterone or progestin in a hormone therapy regimen shapes the safety profile, bleeding pattern, sleep effect, and out-of-pocket cost. The category includes bioidentical oral micronized progesterone, synthetic progestins such as medroxyprogesterone acetate and norethindrone, progestin-releasing intrauterine devices, and compounded creams or troches. This guide compares the evidence for each, summarizes what major societies recommend, and explains how telehealth menopause clinics typically approach the prescription. It is intended as an editorial overview, not personalized medical advice.

Key facts at a glance

• Micronized progesterone is structurally identical to the hormone the ovaries produce; synthetic progestins are not.
• Endometrial protection requires adequate progesterone or progestin exposure when estrogen is used in a woman with a uterus.¹
• The E3N cohort linked micronized progesterone with a smaller relative breast cancer signal than medroxyprogesterone acetate over five years of use.²
• Compounded transdermal progesterone creams have not demonstrated reliable endometrial protection in randomized trials.³

What are the main progesterone types

Three broad progesterone types dominate prescribing in 2026. The first is bioidentical micronized progesterone, sold under the brand Prometrium and as authorized generics, taken orally at 100 mg or 200 mg or used vaginally off-label. The second is the synthetic progestin family, which includes medroxyprogesterone acetate (Provera), norethindrone acetate, drospirenone, dydrogesterone, and levonorgestrel. The third is custom-compounded progesterone, prepared by 503A or 503B pharmacies as creams, troches, capsules, or pellets at non-standardized strengths.

The 2022 NAMS Hormone Therapy Position Statement is explicit that endometrial protection is required whenever systemic estrogen is prescribed to a woman with an intact uterus.¹ The statement lists micronized progesterone, several oral progestins, and the 52 mg levonorgestrel intrauterine system as acceptable options for that protection. NAMS does not endorse compounded progesterone creams for endometrial protection because dosing and absorption have not been adequately validated.¹

The Endocrine Society 2015 guideline similarly differentiates progesterone from progestins on pharmacology grounds, noting that binding affinity, metabolites, and androgenic or glucocorticoid activity vary across the synthetic class.⁴ That pharmacologic heterogeneity is why side-effect profiles — from bloating to mood changes to lipid effects — differ between, for example, drospirenone and medroxyprogesterone acetate.

How the categories differ on safety and side effects

Head-to-head randomized trials between progesterone types are limited. The largest body of comparative evidence comes from the French E3N prospective cohort of about 80,000 postmenopausal women followed for over a decade. In E3N, estrogen plus micronized progesterone was associated with a relative breast cancer risk of about 1.00 over roughly five years of use, while estrogen plus synthetic progestins carried a relative risk closer to 1.69.² A 2014 update extended these findings but emphasized that observational design cannot establish causation.

The Women's Health Initiative (WHI), which used conjugated equine estrogen plus medroxyprogesterone acetate, found increased breast cancer incidence in the combined arm after about 5.6 years and informed the FDA boxed warning on combined HRT.⁵ WHI did not test micronized progesterone, which is one reason later European guidelines treat the two regimens differently.

Sleep is another differentiator. Oral micronized progesterone is metabolized into allopregnanolone, a GABA-A receptor positive modulator, which is why some women report improved sleep onset at the 200 mg bedtime dose. Synthetic progestins do not produce the same metabolites and are not typically prescribed for sleep effect.⁴ Mood, bloating, and breakthrough bleeding patterns also vary by molecule and route — vaginal micronized progesterone, for example, has lower systemic side-effect burden than oral dosing.

Compounded creams are the highest-uncertainty category. The 2020 National Academies report on compounded bioidentical hormone therapy concluded that there is insufficient evidence on dosing accuracy, sterility, and clinical equivalence to FDA-approved products.³ ACOG Committee Opinion 532 reiterates that custom-compounded hormone therapy should not be presumed safer or more effective than FDA-approved alternatives.⁶

Comparing options: regimens, dosing, and routes

The most common adult regimen pairs systemic estradiol with oral micronized progesterone 100 mg nightly for continuous combined therapy or 200 mg nightly for 12-14 days each month for cyclic therapy.¹ Cyclic dosing typically produces a predictable withdrawal bleed and is often selected for perimenopausal women still cycling, while continuous dosing aims for amenorrhea and is more common after menopause.

Synthetic progestin choices include medroxyprogesterone acetate 2.5-5 mg daily, norethindrone acetate 0.1-0.5 mg daily, and combination products such as estradiol-norethindrone or estradiol-drospirenone tablets. The 52 mg levonorgestrel intrauterine system (Mirena, Liletta) is FDA-approved for endometrial protection during estrogen therapy for up to 8 years and is often selected for women with heavy menstrual bleeding or who want long-acting contraception simultaneously.⁷

Compounded options remain available through some clinics. NAMS and ACOG both recommend that, when bioidentical progesterone is clinically indicated, FDA-approved micronized progesterone should be tried first because it has documented bioavailability and endometrial safety data.¹ ⁶ This editorial position is not a directive — readers should discuss the specific regimen, including cyclic versus continuous dosing and oral versus vaginal route, with a clinician.

Telehealth provider options

Several telehealth menopause platforms prescribe progesterone after a clinical intake. Differentiators vary on insurance acceptance, clinician credentials, and which formulations are offered.

• Midi Health — NAMS-certified clinicians, accepts most major commercial insurance plans, prescribes FDA-approved micronized progesterone and standard progestin combinations.
• Winona — cash-pay subscription model, includes oral micronized progesterone in its menopause regimens shipped via partner pharmacy.
• Alloy Women's Health — async-first, flat monthly pricing, prescribes FDA-approved bioidentical progesterone and estradiol.
• Gennev — board-certified OB-GYNs via video, accepts some insurance plans, prescribes standard FDA-approved hormone therapy components.

These descriptions reflect publicly available information and should not be read as rankings. Coverage, formulary, and clinician availability change frequently.

Safety, contraindications, and when to see a clinician in person

Absolute and relative contraindications to systemic hormone therapy — including unexplained vaginal bleeding, active or recent breast cancer, history of estrogen-dependent neoplasia, active venous thromboembolism, recent stroke or myocardial infarction, active liver disease, and pregnancy — apply across progesterone types when used with estrogen.¹ Some progestin-only regimens may still be used in subsets of these populations under specialist guidance, but that determination is clinician-led.

Side effects that warrant prompt clinical contact include heavy or prolonged unexpected bleeding, chest pain, unilateral leg swelling, sudden severe headache, vision changes, or new breast lumps. Routine surveillance for women on combined HRT typically includes annual breast and pelvic exams and adherence to age-appropriate mammography and cervical cancer screening per USPSTF and ACOG recommendations.⁶

Anyone with a personal or strong family history of breast or ovarian cancer, BRCA1/2 status, prior venous thromboembolism, or migraine with aura should discuss progesterone type selection in person with a clinician who can review full history and family pedigree. Drug interactions also matter: cytochrome P450 3A4 inducers such as rifampin, carbamazepine, and St. John's wort can reduce oral progesterone levels, while inhibitors such as ketoconazole and certain HIV protease inhibitors may elevate them.⁴ Women with active gallbladder disease, hypertriglyceridemia, or severe hepatic impairment should also flag those histories during intake.

Endometrial surveillance protocols vary by regimen. For women on continuous combined therapy, persistent or recurrent bleeding after the first six months typically prompts transvaginal ultrasound or endometrial biopsy. For women on cyclic regimens, bleeding outside the expected withdrawal window is the corresponding trigger.¹ These thresholds are clinician-set and should be confirmed with the prescribing provider.

Cost and insurance considerations

Cash prices for generic oral micronized progesterone 100 mg run roughly $15-$40 for a 30-day supply at major U.S. retail pharmacies as of 2026, with most commercial insurance plans covering the generic at standard tier copays. Generic medroxyprogesterone acetate 2.5 mg is similarly priced at $10-$25 cash. The 52 mg levonorgestrel intrauterine system has a list price near $1,000 but is typically covered by commercial insurance and many Medicaid plans under contraceptive coverage provisions.⁷

Compounded progesterone creams and troches are generally not covered by commercial insurance and cost roughly $60-$200 per month out-of-pocket depending on pharmacy and strength.³ Telehealth menopause platforms that operate on a subscription model — including Winona and Alloy Women's Health — bundle the visit fee, ongoing clinician access, and a partner-pharmacy supply into a single monthly charge typically in the $35-$85 range, with medication costs sometimes included and sometimes billed separately. Insurance-accepting platforms such as Midi Health and Gennev route prescriptions to a pharmacy of choice, which may yield lower medication cost when the generic is covered.

Frequently asked questions

What is the difference between progesterone and progestin? Progesterone is the hormone the ovaries produce; progestins are synthetic compounds that bind the progesterone receptor but differ structurally. Micronized progesterone (Prometrium) is bioidentical to endogenous progesterone, while medroxyprogesterone acetate, norethindrone, and drospirenone are synthetic progestins with distinct side-effect profiles.

Is micronized progesterone safer than synthetic progestins? Observational data from the French E3N cohort and others suggest micronized progesterone may have a more favorable breast cancer risk profile than medroxyprogesterone acetate when combined with estrogen, but head-to-head randomized trials are limited. NAMS lists micronized progesterone as a reasonable first-line option for endometrial protection.

Can progesterone be taken without estrogen? Some clinicians prescribe progesterone alone for perimenopausal sleep disruption or heavy bleeding, though this use is off-label. Evidence is mixed. Anyone considering progesterone monotherapy should discuss risks, benefits, and dosing with a clinician familiar with menopausal hormone therapy.

Does compounded progesterone cream work? Compounded transdermal progesterone creams have not been shown in randomized trials to deliver consistent serum levels adequate for endometrial protection. ACOG, NAMS, and the Endocrine Society do not recommend compounded progesterone creams as a substitute for FDA-approved oral or vaginal micronized progesterone when a woman is also taking estrogen.

Does insurance cover micronized progesterone? Most U.S. commercial plans cover generic oral micronized progesterone (100 mg and 200 mg capsules). Compounded creams, troches, and pellets are generally not covered. Telehealth menopause platforms typically route prescriptions through retail pharmacies that accept commercial insurance.

How is the right progesterone type chosen? Clinicians weigh whether a woman still has a uterus, her bleeding pattern, sleep complaints, breast cancer family history, prior progestin tolerance, and cost. There is no universal best option, and reassessment is recommended annually or when symptoms change.

Sources

1. The 2022 Hormone Therapy Position Statement of The North American Menopause Society. Menopause. 2022;29(7):767-794. https://pubmed.ncbi.nlm.nih.gov/35797481/
2. Fournier A, Berrino F, Clavel-Chapelon F. Unequal risks for breast cancer associated with different hormone replacement therapies: results from the E3N cohort study. Breast Cancer Res Treat. 2008;107(1):103-111. https://pubmed.ncbi.nlm.nih.gov/17333341/
3. National Academies of Sciences, Engineering, and Medicine. The Clinical Utility of Compounded Bioidentical Hormone Therapy. 2020. https://nap.nationalacademies.org/catalog/25791/
4. Stuenkel CA, Davis SR, Gompel A, et al. Treatment of Symptoms of the Menopause: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2015;100(11):3975-4011. https://pubmed.ncbi.nlm.nih.gov/26444994/
5. Rossouw JE, Anderson GL, Prentice RL, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA. 2002;288(3):321-333. https://pubmed.ncbi.nlm.nih.gov/12117397/
6. ACOG Committee Opinion No. 532: Compounded bioidentical menopausal hormone therapy. Obstet Gynecol. 2012;120(2 Pt 1):411-415 (reaffirmed 2020). https://www.acog.org/clinical/clinical-guidance/committee-opinion/articles/2012/08/compounded-bioidentical-menopausal-hormone-therapy
7. U.S. Food and Drug Administration. Mirena (levonorgestrel-releasing intrauterine system) — Prescribing Information. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/021225s041lbl.pdf
8. Schindler AE, Campagnoli C, Druckmann R, et al. Classification and pharmacology of progestins. Maturitas. 2008;61(1-2):171-180. https://pubmed.ncbi.nlm.nih.gov/19434889/

Related brands & guides

Updated 2026-05-30. Reviewed by Jane Smith, MD.